Generex Launches Oral Insulin for Diabetes Management

Generex announces a partnership with a company to promote their oral insulin with more than a 1000 person sales force in India.

Generex Biotechnology Corporation the leader in drug delivery for metabolic diseases through the inner lining of the mouth, and Shreya Life Sciences Pvt. Ltd., the Company’s importation, marketing and distribution licensee in India and the fourth largest marketer of insulin in India, jointly announced last Friday, the launch of commercial retail sales of Generex Oral-lyn(tm) in India. Generex Oral-lyn is approved in India for the treatment of adults and children with Type 1 and Type 2 diabetes and will be marketed and sold in India under the brand name “Oral-Recosulin”.

 Shreya will offer the product through its sales force of more than 1,000 people and will implement a continuing medical education program to introduce the product to endocrinologists, diabetologists and physicians in India and expects that the product will eventually be available in more than 2,500 pharmacies in the country.

The launch of Oral-Recosulin, which offers a simple, convenient, fast, effective, flexible, familiar and pain-free alternative to prandial injections of insulin, coincides with the United Nations’ World Diabetes Day, celebrated annually on November 14. The product is expected to be widely available for retail purchase in India before the end of the month.
“It is with great anticipation and enthusiasm that we launch this innovative new product for the Indian diabetes market. Diabetes is reaching epidemic proportions in India, with over 40.8 million diagnosed patients and an estimated 35.9 million additional people with pre-diabetic conditions which, if not properly treated and managed, could lead to full-blown diabetes,” said Sujit Kumar Singh, the Chairman & Managing Director of Shreya. “Early intervention with insulin therapy could delay the onset and progression of diabetes and its numerous complications. Generex Oral-lyn(tm), as a convenient and pain-free alternative to prandial insulin injections, could encourage insulin therapy among those patients who presently avoid injections. We look forward to our collaboration with Generex to revolutionize the treatment of diabetes in India.”

Generex Oral-lyn(tm) is Generex’s flagship product, a proprietary oral insulin spray that has been approved in India by the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, for importation, commercial marketing and sale for the treatment of Type 1 and Type 2 diabetes. Generex Oral-lyn(tm) is the first non-injectable buccal insulin approved in India. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(tm) does not have pulmonary side effects. Generex Oral-lyn(tm) is safely and efficiently delivered without pain via the Company’s proprietary RapidMist(tm) device, which looks like a simple asthma inhaler, but provides complete absorption through the buccal mucosa (lining of the mouth) with no deposit in the lungs.